Australia-wide dispatch

Quantified
Peptides
Cagrilintide 10mg — research peptide, lyophilised powder in a glass vial, supplied by Quantified Peptides, Sydney, Australia. For in-vitro research use only.

Peptides

Cagrilintide

Cagrilintide (AM833). Supplied as a lyophilised powder in 10mg vials.

Supplied as lyophilised powder in a 10mg specification. Storage: -20°C · Keep dry, avoid light. Dispatched from Sydney, Australia-wide.

Product information

About Cagrilintide

Cagrilintide (AM833)

Research background as published in the scientific literature. Supplied for in-vitro laboratory research only; nothing here is a claim about use in humans or animals.

Cagrilintide (AM833) is a long-acting amylin analogue developed by Novo Nordisk. Amylin is a 37-amino acid peptide co-secreted with insulin from pancreatic beta cells that plays a role in postprandial glucose regulation and satiety signalling.

Research has examined cagrilintide's ability to activate amylin receptors (CALCR + RAMPs) to modulate food intake, gastric emptying, and body weight. Phase 2 trials examining the combination of cagrilintide with semaglutide (CagriSema) have reported substantial body weight effects, with Phase 3 trials currently underway.

Type
Long-acting amylin analogue
Research Areas
Satiety signalling, metabolic regulation, weight research
Target
CALCR + RAMP1/2/3 (amylin receptors)
Developer
Novo Nordisk
Trial Status
Phase 3 (CagriSema)
Half-life
~7 days (research models)
Co-target
GLP-1 receptor (in combination)
Key Research
CagriSema Phase 3 programme
  1. 01Amylin Receptor AgonismCagrilintide is a long-acting analogue of amylin, a peptide co-secreted with insulin from pancreatic beta cells. Research examines its effects on appetite signalling via area postrema and nucleus tractus solitarius pathways.
  2. 02Satiety & Food IntakeLaboratory and clinical research has investigated cagrilintide's role in reducing caloric intake and modulating meal size through central satiety pathways. Studies examine synergistic effects with GLP-1 receptor agonists.
  3. 03Metabolic RegulationResearch has examined cagrilintide's effects on glucose homeostasis, gastric emptying rate, and body composition. Phase 3 clinical trials (CagriSema) are examining combined cagrilintide + semaglutide treatment.

References

  1. 1Enebo LB et al. Safety, tolerability, pharmacokinetics, and pharmacodynamics of cagrilintide. Lancet. 2021;397(10286):1736-1748.
  2. 2Novo Nordisk. CagriSema Phase 3 trials (NCT05035095). ClinicalTrials.gov.
  3. 3PubMed: pubmed.ncbi.nlm.nih.gov/?term=cagrilintide
  4. 4Aronne LJ et al. Cagrilintide 2.4 mg plus semaglutide 2.4 mg combination. NEJM Evidence 2023.

Ships from Sydney

Australia-wide, plain unbranded packaging. Dispatched on business days.

If it arrives wrong

Replaced, resent or refunded. You do not have to argue for it.

Also in this range.

Compounds the supplier files alongside this one.

View the range